Daniel F. Hayes MD

Dr. Hayes is the Stuart A. Padnos Professor of Breast Cancer Research and co-Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center. He has a long history of clinical and translational breast cancer research regarding new drug development/clinical trials and particularly development and clinical utility of biomarkers. Dr. Hayes has been principally responsible for introduction and adoption of several circulating tumor markers, including CA15-3(which identifies MUC-1 protein), extracellular domain of HER2, and more recently enumeration and characterization of circulating tumor cells (CTC). He has also been a leader in tissue-based markers of prognosis and prediction to therapies, such as neo-vascularization, HER-2, and the 21-gene recurrence score. He and his colleagues in the Consortium on Breast Cancer Pharmacogenomics (COBRA) have made sentinel discoveries regarding the effects of inherited, germline, genet single nucleotide polymorphisms on metabolism and clinical activity of endocrine treatments of breast cancer, such as tamoxifen and the aromatase inhibitors.